Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours

Letter to the Editor

References

  1. 1.
    Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27(3):273–82.CrossRefPubMedGoogle Scholar
  2. 2.
    Froidevaux S, Heppeler A, Eberle AN, Meier AM, Hausler M, Beglinger C, et al. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology 2000;141(9):3304–12.CrossRefGoogle Scholar
  3. 3.
    Waldherr C, Pless M, Maecke H, Schumacher T, Crazzolara A, Nitzsche E, et al. Tumor response and clincical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 2002;43:610–6.PubMedGoogle Scholar
  4. 4.
    Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S, Lopera Sierra M, et al. 90Y-DOTA-d-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002;66:393–8.CrossRefGoogle Scholar
  5. 5.
    Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439–47.CrossRefPubMedGoogle Scholar
  6. 6.
    Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-d-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12(7):941–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Kwekkeboom D, Bakker W, Kam BLR, Teunissen J, Kooij P, Herder W, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417–22.PubMedGoogle Scholar
  8. 8.
    Konijnenberg MW. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients? Cancer Biother Radiopharm 2003;18(4):619–25.CrossRefGoogle Scholar
  9. 9.
    Teunissen J, Kwekkeboom D, Krenning E. Quality of life in patients with gastro-entero- pancreatic tumors treated with [177Lu- DOTA0,Tyr3]octreotate. J Clin Oncol 2004;22:2724–9.CrossRefGoogle Scholar
  10. 10.
    Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. 86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT 487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510–8.PubMedGoogle Scholar
  11. 11.
    De Jong M, Valkema R, Van Gameren A, Van Boven H, Bex A, Van De Weyer EP, et al. Inhomogeneous localization of radioactivity in the human kidney after injection of [111In-DTPA]octreotide. J Nucl Med 2004;45(7):1168–71.Google Scholar
  12. 12.
    Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium-90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001;37(4):847–51.Google Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  1. 1.Institute of Nuclear MedicineUniversity Hospital BaselBaselSwitzerland
  2. 2.Division of Radiological ChemistryUniversity Hospital BaselBaselSwitzerland

Personalised recommendations